Findings

What do systematic reviews say?

2,234 questions · 2,325 findings · 216 reviews · Airways

Sort:Best matchNewestHighest certainty Download CSV

No studies found 249 · 10.7%GRADE not reported 107 · 4.6%Very low 276 · 11.9%Low 751 · 32.3%Moderate 718 · 30.9%High 224 · 9.6%

Macrolides vs placebo

Use of rescue medication · adults and children with chronic asthma

1 finding from 1 review

Macrolides versus placebo for chronic asthma 2021 · Cochrane Headline outcomes only
no estimate extracted
4 studies · 314 participants
Low

Macrolides vs placebo

FEV1 (L) Weighted mean study duration: 28 weeks · adults and children with chronic asthma

1 finding from 1 review

Macrolides versus placebo for chronic asthma 2021 · Cochrane Headline outcomes only
no estimate extracted
10 studies · 1046 participants
Low

Macrolides vs placebo

Serious adverse events (including mortality) · adults and children with chronic asthma

Macrolides showed no clear difference in serious adverse events (including mortality) Weighted mean study… compared with placebo (low certainty).

1 finding from 1 review

Macrolides versus placebo for chronic asthma 2021 · Cochrane Headline outcomes only
OR 0.8 [0.49, 1.31]
8 studies · 854 participants
Low

Endothelin receptor antagonists vs placebo

Meters change from baseline in 6MWD · pulmonary arterial hypertension

1 finding from 1 review

Endothelin receptor antagonists for pulmonary arterial hypertension 2021 · Cochrane Headline outcomes only
no estimate extracted
14 studies · 2739 participants
Moderate

Endothelin receptor antagonists vs placebo

Proportion of participants with improved functional class mean duration of study 16.8 weeks · pulmonary arterial hypertension

Endothelin receptor antagonists probably leads to higher proportion of participants with improved functional class mean… compared with placebo (moderate certainty).

1 finding from 1 review

Endothelin receptor antagonists for pulmonary arterial hypertension 2021 · Cochrane Headline outcomes only
OR 1.41 [1.16, 1.7]
15 studies · 3060 participants
Moderate

Endothelin receptor antagonists vs placebo

Change from baseline in BDI mean duration of study 14.3 weeks · pulmonary arterial hypertension

1 finding from 1 review

Endothelin receptor antagonists for pulmonary arterial hypertension 2021 · Cochrane Headline outcomes only
no estimate extracted
7 studies · 788 participants
Low

Endothelin receptor antagonists vs placebo

Mortality mean duration of study 30.2 weeks · pulmonary arterial hypertension

Endothelin receptor antagonists showed no clear difference in mortality mean duration of study 30.2 weeks compared with placebo (low certainty).

1 finding from 1 review

Endothelin receptor antagonists for pulmonary arterial hypertension 2021 · Cochrane Headline outcomes only
OR 0.78 [0.58, 1.07]
12 studies · 2889 participants
Low

Endothelin receptor antagonists vs placebo

Change from baseline in mean PAP (mmHg) mean duration of study 17.1 weeks · pulmonary arterial hypertension

1 finding from 1 review

Endothelin receptor antagonists for pulmonary arterial hypertension 2021 · Cochrane Headline outcomes only
no estimate extracted
8 studies · 729 participants
Moderate

Endothelin receptor antagonists vs placebo

Change from baseline in PVR (dyn/s/cm5) mean duration of study 15.7 weeks · pulmonary arterial hypertension

1 finding from 1 review

Endothelin receptor antagonists for pulmonary arterial hypertension 2021 · Cochrane Headline outcomes only
no estimate extracted
7 studies · 586 participants
Moderate

Endothelin receptor antagonists vs placebo

Hepatic toxicity mean duration of study 25 weeks · pulmonary arterial hypertension

Endothelin receptor antagonists showed no clear difference in hepatic toxicity mean duration of study 25 weeks compared with placebo (moderate certainty).

1 finding from 1 review

Endothelin receptor antagonists for pulmonary arterial hypertension 2021 · Cochrane Headline outcomes only
OR 1.88 [0.91, 3.9]
11 studies · 2250 participants
Moderate

Pulmonary rehabilitation vs no pulmonary rehabilitation

Meters change from baseline in 6MWD · interstitial lung disease

2 findings from 1 review

Pulmonary rehabilitation for interstitial lung disease 2021 · Cochrane Headline outcomes only
no estimate extracted
13 studies · 585 participants
Moderate
Pulmonary rehabilitation for interstitial lung disease 2021 · Cochrane Headline outcomes only
no estimate extracted
6 studies · 321 participants
Moderate

Pulmonary rehabilitation vs no pulmonary rehabilitation

Change in peak work capacity · idiopathic pulmonary fibrosis

1 finding from 1 review

Pulmonary rehabilitation for interstitial lung disease 2021 · Cochrane Headline outcomes only
no estimate extracted
2 studies · 62 participants
Low

Pulmonary rehabilitation vs no pulmonary rehabilitation

Change in dyspnoea score · idiopathic pulmonary fibrosis

1 finding from 1 review

Pulmonary rehabilitation for interstitial lung disease 2021 · Cochrane Headline outcomes only
no estimate extracted
4 studies · 155 participants
Low

Pulmonary rehabilitation vs no pulmonary rehabilitation

Change in quality of life · idiopathic pulmonary fibrosis

1 finding from 1 review

Pulmonary rehabilitation for interstitial lung disease 2021 · Cochrane Headline outcomes only
no estimate extracted
6 studies · 194 participants
Moderate

Pulmonary rehabilitation vs no pulmonary rehabilitation

Change in quality of life at long‐term · idiopathic pulmonary fibrosis

1 finding from 1 review

Pulmonary rehabilitation for interstitial lung disease 2021 · Cochrane Headline outcomes only
no estimate extracted
2 studies · 89 participants
Low

Pulmonary rehabilitation vs no pulmonary rehabilitation

Long‐term survival (incidence of mortality) · idiopathic pulmonary fibrosis

Pulmonary rehabilitation showed no clear difference in long‐term survival (incidence of mortality) compared with no pulmonary rehabilitation (low certainty).

1 finding from 1 review

Pulmonary rehabilitation for interstitial lung disease 2021 · Cochrane Headline outcomes only
OR 0.32 [0.08, 1.19]
3 studies · 127 participants
Low

Pulmonary rehabilitation vs no pulmonary rehabilitation

Change in peak work capacity · interstitial lung disease

1 finding from 1 review

Pulmonary rehabilitation for interstitial lung disease 2021 · Cochrane Headline outcomes only
no estimate extracted
4 studies · 159 participants
Low

Pulmonary rehabilitation vs no pulmonary rehabilitation

Change in dyspnoea score · interstitial lung disease

1 finding from 1 review

Pulmonary rehabilitation for interstitial lung disease 2021 · Cochrane Headline outcomes only
no estimate extracted
7 studies · 348 participants
Low

Pulmonary rehabilitation vs no pulmonary rehabilitation

Change in quality of life · interstitial lung disease

1 finding from 1 review

Pulmonary rehabilitation for interstitial lung disease 2021 · Cochrane Headline outcomes only
no estimate extracted
11 studies · 478 participants
Moderate

Pulmonary rehabilitation vs no pulmonary rehabilitation

Change in quality of life at long‐term · interstitial lung disease

1 finding from 1 review

Pulmonary rehabilitation for interstitial lung disease 2021 · Cochrane Headline outcomes only
no estimate extracted
4 studies · 240 participants
Low